Combination treatment for large b-cell lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study tests a new combination of drugs for people with large b-cell lymphoma that has come back or not responded to the first treatment. It aims to see if this combination can help control the cancer and prepare for a type of cell therapy called liso-cel.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of large b-cell lymphoma, such as diffuse large b-cell lymphoma or high-grade b-cell lymphoma.
- Your lymphoma came back or did not respond after your first treatment (or you are not eligible for a stem cell transplant).
- You are at least 18 years old.
- You are able to do daily activities with some help (ECOG score 0-2).
- You have not had CAR T-cell therapy or certain other treatments before.
- You do not have active hepatitis B or C, or other serious infections.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug combo for people with an aggressive type of large b-cell lymphoma. It aims to see if adding the new drug to standard chemo plus an antibody therapy is safe and works better.
This trial tests whether combining a short course of radiation with a targeted antibody drug (glofitamab) can help people with aggressive large B-cell lymphoma that came back after treatment, especially if they have bulky tumors. It aims to find a new option for hard-to-treat cases.
This study tests a combination of CAR-T cell therapy and a drug called glofitamab for people with large B-cell lymphoma that has come back or not responded to treatment. The goal is to see if this combo can help those with high-risk features.
This trial tests a combination of three drugs (glofitamab, a PD-1 antibody, and lenalidomide) for people with relapsed or refractory large B-cell lymphoma that has a TP53 change. The goal is to see if this combination works better for patients who cannot have a stem cell transplant.
This study tests a new combination of four drugs—sonrotoclax, glofitamab, gemcitabine, and oxaliplatin—in people with large B-cell lymphoma that has come back or not responded to earlier treatment. The goal is to see if this combination can shrink or control the lymphoma.
This trial tests a combination of two immunotherapy drugs (rimegepant and glofitamab) plus a special cell therapy called CD19 CAR-T for people with large B-cell lymphoma that has not responded to or has returned after previous treatment. The goal is to see if this combination can better control the lymphoma and improve outcomes.
Hear when a new Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.